An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via an injected monoclonal antibody designed to inhibit the action of a protein called PCSK9, which is involved with the regulation of LDL (bad cholesterol). Sanofi (SNY) and Regeneron (REGN) are believed to have progressed the most in developing products that target PCSK9.